Overview

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)

Status:
Not yet recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib. Each of these agents separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and each of which appear to have separate and complementary mechanisms of action.

Phase:

Phase 2

Details

Lead Sponsor:

Leidos Life Sciences

Collaborator:

United States Department of Defense

Treatments:

Celecoxib
Famotidine